MARC E ROTHENBERG, M.D.
Osteopathic Medicine at Burnet Ave, Cincinnati, OH
License number
Ohio 35.072107
Category
Osteopathic Medicine
Type
Allergy & Immunology
Address
Address
3333 Burnet Ave, Cincinnati, OH 45229
Phone
(513) 636-6771
Personal information
See more information about MARC E ROTHENBERG at radaris.comName
Address
Phone
2624 S Green Rd, Beachwood, OH 44122
9343 Lansford Dr, Blue Ash, OH 45242
9343 Lansford Dr, Blue Ash, OH 45242
27286 Blossom Blvd, North Olmsted, OH 44070
27286 Blossom Blvd, Westlake, OH 44145
Organization information
See more information about MARC E ROTHENBERG at bizstanding.comMarc E Rothenberg MD
3333 Burnet Ave #MLC9002, Cincinnati, OH 45229
Categories:
Pediatrics Physicians & Surgeons
Phone:
(513) 636-6771 (Phone)
Professional information
Professor Of Pediatrics At Cincinnati Children's Hospital Medical Center
Position:
Professor of Pediatrics at Cincinnati Children's Hospital Medical Center
Location:
Cincinnati Area
Industry:
Health, Wellness and Fitness
Work:
Cincinnati Children's Hospital Medical Center
-
Professor of Pediatrics
Education:
Harvard Medical School 1983 - 2000
Brandeis University 1979 - 1983
B.A., chemistry
Brandeis University 1979 - 1983
B.A., chemistry
Treatment For Asthma Or Allergies
US Patent:
2003016, Sep 4, 2003
Filed:
Feb 28, 2003
Appl. No.:
10/377998
Inventors:
Marc Rothenberg - Cincinnati OH, US
Nives Zimmermann - Cincinnati OH, US
Nives Zimmermann - Cincinnati OH, US
International Classification:
A61K038/17, C12Q001/68, G01N033/53
US Classification:
514/012000, 435/006000, 435/007100
Abstract:
Several genes are upregulated in the lung of asthma or allergy sufferers. Many of the genes up-regulated in asthma are involved in arginine metabolism in the lung. Moreover, a set of 291 signature genes was found that can be used to indicate a patient's predilection for developing asthma or the patient's degree of suffering. Also, a set of 59 signature genes were found that indicate a patient's predilection for developing allergies. Many of the up-regulated genes relating to asthma were from the arginine metabolic pathway. Other genes, such as ADAM8, SPRR2A and SPRR2B were also strongly up-regulated in asthma. Treatment of asthma may be accomplished by administering compositions which decrease the levels of Arginase I, Arginase II, CAT2, or other arginase pathway members in the lung. Additionally, detection of altered levels of these proteins or the mRNA encoding them may be useful to diagnose the presence of asthma in a patient.
Method Of Detecting The Presence Of Asthma Or Allergies In A Patient
US Patent:
7879547, Feb 1, 2011
Filed:
Apr 16, 2007
Appl. No.:
11/735954
Inventors:
Marc E. Rothenberg - Cincinnati OH, US
Nives Zimmermann - Cincinnati OH, US
Nives Zimmermann - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Several genes are upregulated in the lung of asthma or allergy sufferers. Many of the genes up-regulated in asthma are involved in arginine metabolism in the lung. Moreover, a set of 291 signature genes was found that can be used to indicate a patient's predilection for developing asthma or the patient's degree of suffering. Also, a set of 59 signature genes were found that indicate a patient's predilection for developing allergies. Many of the up-regulated genes relating to asthma were from the arginine metabolic pathway. Other genes, such as ADAM8, SPRR2A and SPRR2B were also strongly up-regulated in asthma. Treatment of asthma may be accomplished by administering compositions which decrease the levels of Arginase I, Arginase II, CAT2, or other arginase pathway members in the lung. Additionally, detection of altered levels of these proteins or the mRNA encoding them may be useful to diagnose the presence of asthma in a patient.
Methods And Compositions For Mitigating Eosinophilic Esophagitis By Modulating Levels And Activity Of Eotaxin-3
US Patent:
2011019, Aug 11, 2011
Filed:
Mar 18, 2011
Appl. No.:
13/051873
Inventors:
Marc Elliot Rothenberg - Cincinnati OH, US
Assignee:
CHILDREN'S HOSPITAL MEDICAL CENTER - Cincinnati OH
International Classification:
C12N 5/00
US Classification:
435375
Abstract:
Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed.
Cytokine Inhibition Of Eosinophils
US Patent:
2004014, Jul 22, 2004
Filed:
Jan 7, 2004
Appl. No.:
10/752659
Inventors:
Marc Rothenberg - Cincinnati OH, US
Patricia Fulkerson - Cincinnati OH, US
Patricia Fulkerson - Cincinnati OH, US
International Classification:
A61K038/19
US Classification:
424/085100
Abstract:
A composition and method to alter eosinophil function and recruitment. An allergen-induced chemokine with inhibitory activity on eosinophils, monokine induced by interferon (MIG) and/or an IFN--inducible protein of 10 kDa (IP-10), is administered in a pharmaceutically acceptable dose and formulation. The composition is used for prophylaxis and therapy of diseases in which eosinophilia occurs and may be administered, for example, to allergic patients and asthmatic patients.
Methods Of Determining Efficacy Of Glucocorticoid Treatment Of Eosinophilic Esophagitis
US Patent:
2011030, Dec 8, 2011
Filed:
Dec 1, 2009
Appl. No.:
13/132295
Inventors:
Marc E. Rothenberg - Cincinnati OH, US
Julie Caldwell - Cincinnati OH, US
Julie Caldwell - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
C12Q 1/68, C40B 30/00, G01N 33/566
US Classification:
506 7, 435 612, 436501
Abstract:
The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products.
Il-13 Induced Gene Signature For Eosinophilic Esophagitis
US Patent:
2012000, Jan 5, 2012
Filed:
Dec 1, 2009
Appl. No.:
12/628992
Inventors:
Marc Elliott Rothenberg - Cincinnati OH, US
Assignee:
Cincinnati Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 31/56, C40B 30/04, A61P 1/00, G01N 33/566, A61P 29/00, C07H 21/00, C12Q 1/68
US Classification:
514180, 536 2431, 506 9, 435 612, 435 792
Abstract:
The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products induced by IL-13.
Regulation Of Ccr3 Expression
US Patent:
2002015, Oct 17, 2002
Filed:
Feb 5, 2002
Appl. No.:
10/068067
Inventors:
Marc Rothenberg - Cincinnati OH, US
Nives Zimmermann - Cincinnati OH, US
Nives Zimmermann - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K048/00, C12N015/87
US Classification:
435/455000, 514/044000
Abstract:
A method of regulating CCR3 expression by transcriptional and mRNA control. In one embodiment, regulation occurs in a non-promoter, regulatory region of the CCR3 gene, such as untranslated exons 1, 2, and/or 3. This type of regulation has a preferential effect on eosinophilic cells; such selectivity advantageously produces less deleterious side effects when administered in a pharmaceutical preparation. Regulation of CCR3 expression by promoter targeting also presents a method to reduce CCR3 expression in a cell-specific or nonspecific manner. Other types of regulatory compounds do not demonstrate such a preferential effect. Because CCR3 is expressed on cells involved in inflammatory reactions, regulations of CCR3 provides an intervention site for asthma, as well as other allergic, inflammatory and hypersensitivity reactions, eosinophil-mediated diseases, and infectious disorders.
Cytokine Inhibition Of Eosinophils
US Patent:
2005019, Sep 1, 2005
Filed:
Mar 28, 2005
Appl. No.:
11/091288
Inventors:
Marc Rothenberg - Cincinnati OH, US
Patricia Fulkerson - Cincinnati OH, US
Patricia Fulkerson - Cincinnati OH, US
International Classification:
A61K038/19
US Classification:
424085100
Abstract:
The cytokine CXCL9 (MIG) inhibited eosinophil responses by a CCR3- and Rac2-dependent mechanism.
Evaluation Of Eosinophilic Esophagitis
US Patent:
2009026, Oct 29, 2009
Filed:
Jun 26, 2009
Appl. No.:
12/492456
Inventors:
Marc E. Rothenberg - Cincinnati OH, US
Carine Blanchard - Cincinnati OH, US
Carine Blanchard - Cincinnati OH, US
Assignee:
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER - Cincinnati OH
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.